Shah Rajeev M. - Insider Trading Tracker

Acumen Pharmaceuticals, Inc.

US ˙ NasdaqGS ˙ US00509G2093

Introduction

This page provides a comprehensive analysis of the known insider trading history of Shah Rajeev M.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate Shah Rajeev M. has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:WVE / Wave Life Sciences Ltd.	Director, 10% Owner	28,815
US:CDTX / Cidara Therapeutics, Inc.	Director, 10% Owner	3,365,523
US:TYRA / Tyra Biosciences, Inc.	Director, 10% Owner	10,259,291
US:JANX / Janux Therapeutics, Inc.	Director, 10% Owner	6,250
US:ABOS / Acumen Pharmaceuticals, Inc.	Director, 10% Owner	12,800
US:HOWL / Werewolf Therapeutics, Inc.	Director, 10% Owner	6,237,482
	10% Owner	1,287,858
US:MLYS / Mineralys Therapeutics, Inc.	Director	4,280,051
	Director, 10% Owner	2,324,498
US:ETNB / 89bio, Inc.	Director, 10% Owner	19,554,319
US:VOR / Vor Biopharma Inc.	Director, 10% Owner	37,820,713
US:FDMT / 4D Molecular Therapeutics, Inc.	10% Owner	4,563,211
	Director, 10% Owner	1,471,943
US:FULC / Fulcrum Therapeutics, Inc.	10% Owner	10,229,099
	Director, 10% Owner	2,652,575
US: / AN2 THERAPEUTICS	10% Owner	300,853
	Director, 10% Owner	826,832
US:ELYM / Eliem Therapeutics, Inc.	Director, 10% Owner	2,866,375
US:ITOS / iTeos Therapeutics, Inc.		2,545,510
US:ACRV / Acrivon Therapeutics, Inc.	Director, 10% Owner	7,914,206
	10% Owner	295,844
US:NKTX / Nkarta, Inc.	Director, 10% Owner	10,050,818
US:SPRY / ARS Pharmaceuticals, Inc.	Director, 10% Owner	9,958,073
	Director, 10% Owner	694,755
US:ICVX / Icosavax, Inc.	Director, 10% Owner	0
US:PEPG / PepGen Inc.	Director, 10% Owner	9,179,273
US:SLDB / Solid Biosciences Inc.	Director, 10% Owner	4,192,216
US:DICE / DICE Therapeutics Inc		0
US:BDTX / Black Diamond Therapeutics, Inc.	Director	3,213,828
US:STSA / Satsuma Pharmaceuticals Inc	Director, 10% Owner	0
US:ELVN / Enliven Therapeutics, Inc.		2,122,465
US:FMTX / Forma Therapeutics Holdings Inc	10% Owner	0
US:KALA / KALA BIO, Inc.	10% Owner	7,039,613
US:CTKB / Cytek Biosciences, Inc.	Director, 10% Owner	13,381,054
US:RXST / RxSight, Inc.	10% Owner	2,838,938
	Director	1,098,318
US:SCPH / scPharmaceuticals Inc.	10% Owner	2,727,446
US:PHAT / Phathom Pharmaceuticals, Inc.	10% Owner	3,115,008
US:ORTX / Orchard Therapeutics plc - Depositary Receipt (Common Stock)	Director, 10% Owner	3,215,434
US:ITRM / Iterum Therapeutics plc	10% Owner	0
US:VRDN / Viridian Therapeutics, Inc.	10% Owner	410,686
US:RYTM / Rhythm Pharmaceuticals, Inc.		4,360,860
US:PCVX / Vaxcyte, Inc.	10% Owner	5,001,593
US:CRDF / Cardiff Oncology, Inc.	10% Owner	3,290,000
US:PMVP / PMV Pharmaceuticals, Inc.	10% Owner	0
	10% Owner	0
US:TGTX / TG Therapeutics, Inc.	10% Owner	12,629,868
US:INBX / Inhibrx Biosciences, Inc.	10% Owner	0
US:INZY / Inozyme Pharma, Inc.	10% Owner	0
	10% Owner	0
US:AKUS / Akouos Inc	10% Owner	0
US:VSTM / Verastem, Inc.	10% Owner	16,142,051
	Director	21,528
US:RARX / Ra Pharmaceuticals, Inc.	Director, 10% Owner	0
US:THOR / Synthorx Inc	10% Owner	0
US:KALV / KalVista Pharmaceuticals, Inc.	Director, 10% Owner	1,441,070

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Shah Rajeev M.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ABOS / Acumen Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ABOS / Acumen Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2023-07-21	ABOS	RA CAPITAL MANAGEMENT, LLC	5,161,290	7.7500	5,161,290	7.7500	39,999,998	0	7.4000	-1,806,451	-4.52
2021-07-06	ABOS	RA CAPITAL MANAGEMENT, LLC	1,759,332	16.0000	1,759,332	16.0000	28,149,312
2021-07-06	ABOS	RA CAPITAL MANAGEMENT, LLC	115,668	16.0000	115,668	16.0000	1,850,688